| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
|
| | (N-Crotonyl)-(4S)-isopropyl-2-oxazolidinone Basic information |
| Product Name: | (N-Crotonyl)-(4S)-isopropyl-2-oxazolidinone | | Synonyms: | (4S)-3-[(E)-BUT-2-ENOYL]-4-BENZYL-2-OXAZOLIDINONE;(S)-(+)-4-BENZYL-3-CROTONYL-2-OXAZOLIDINONE;(N-CROTONYL)-(4S)-BENZYL-2-OXAZOLIDINONE;UIC-1005;(R)-4-BENZYL-3-CROTONYL-2-OXAZOLIDINONE;(4S)-N-Crotonyl-4-benzyl-2-oxazolidinone, 99%;(N-Crotonyl)-(R)-4-benzyl-2-oxazolidinone;(4S)-N-Crotonyl-4-benzyl-2-oxazolidinone,99% | | CAS: | 90719-30-5 | | MF: | C14H15NO3 | | MW: | 245.27 | | EINECS: | | | Product Categories: | Peptide | | Mol File: | 90719-30-5.mol |  |
| | (N-Crotonyl)-(4S)-isopropyl-2-oxazolidinone Chemical Properties |
| Melting point | 84-88 °C(lit.) | | Boiling point | 351.0±25.0 °C(Predicted) | | density | 1.205±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: ≥30mg/mL | | form | powder | | pka | -1+-.0.40(Predicted) | | color | white to off-white | | InChI | 1S/C14H15NO3/c1-2-6-13(16)15-12(10-18-14(15)17)9-11-7-4-3-5-8-11/h2-8,12H,9-10H2,1H3/b6-2+/t12-/m0/s1 | | InChIKey | UTZAFVPPWUIPBH-QSLRECBCSA-N | | SMILES | C\C=C\C(=O)N1[C@H](COC1=O)Cc2ccccc2 |
| Safety Statements | 24/25 | | WGK Germany | 3 | | HS Code | 29349990 | | Storage Class | 11 - Combustible Solids |
| | (N-Crotonyl)-(4S)-isopropyl-2-oxazolidinone Usage And Synthesis |
| Uses | Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice [1][2][3]. | | Biochem/physiol Actions | Locostatin is a cell permeable, potent inhibitor of Raf kinase inhibitor protein (RKIP)/Raf1 kinase interaction and an inhibitor of cell migration. | | in vivo | Locostatin (0.5 mg/kg; i.p.; once a day for 7 days) aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice[3]. | Animal Model: | 6 weeks, 18-22 g, male ICR mice (TAA model; injected intraperitoneally with 300 mg/kg TAA once a day for 2 days)[3] | | Dosage: | 0.5 mg/kg | | Administration: | I.p.; once a day for 7 days | | Result: | Decreased the expression of RKIP, led to more severe damage, such as steatosis and hepatic lesions, increased the production of ROS in the liver and TNF-α, IL-6 and IL-1β in the sera of mice with acute liver injury, inhibitd Nrf2 and HO-1 expression in the livers of mice, induced NF-κB activation in the livers of mice,increased the phosphorylation of JNK, p38 and ERK in liver tissues. |
| | References | [1] Beshir AB, et al. Locostatin Disrupts Association of Raf Kinase Inhibitor Protein With Binding Proteins by Modifying a Conserved Histidine Residue in the Ligand-Binding Pocket. For Immunopathol Dis Therap. 2011;2(1):47-58. DOI:10.1615/forumimmundisther.v2.i1.60
[2] Mc Henry KT, et al. A non-antibacterial oxazolidinone derivative that inhibits epithelial cell sheet migration. Chembiochem. 2002 Nov 4;3(11):1105-11. DOI:10.1002/1439-7633(20021104)3:11<1105::AID-CBIC1105>3.0.CO;2-S
[3] Lin X, et al. Inhibition of RKIP aggravates thioacetamide-induced acute liver failure in mice. Exp Ther Med. 2018 Oct;16(4):2992-2998. DOI:10.3892/etm.2018.6542 |
| | (N-Crotonyl)-(4S)-isopropyl-2-oxazolidinone Preparation Products And Raw materials |
|